BCL2 and diffuse large B-cell lymphoma: MYC/BCL-2 double-hit lymphoma (DHL) was associated with resistance or a poor response to therapy and an inferior survival rate in systemic DLBCL.[27–28] MYC/BCL-2 DEL assessed by immunohistochemistry has also been shown to have an adverse prognostic effect on systemic DLBCL, independent of COO subtype.[29–30] In systematic DLBCL, most DHL have a GCB-like origin, whereas the DEL have an ABC-like origin.[31] Our data exhibited that DEL was predominantly observed in non-GCB subtype, and that was similar with systemic DLBCL.